Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Fall 2019 Healthcare Conferences (Stifel NYC, Jefferies London)
27 slides from Indivior Pharmaceuticals's conference presentation, November 2019
Slide 1: Indivior PLC Fall 2019 Healthcare Conferences
Indivior PLC Fall 2019 Healthcare Conferences November 19th (Stifel NYC) and November 21st (Jefferies London)
Slide 2: Forward-looking statements
Forward-looking statements This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from
Slide 3: Shaun Thaxter, Chief Executive Officer
Shaun Thaxter Chief Executive Officer
Slide 4: Compelling vision and leadership position in a growing market
Compelling vision and leadership position in a growing market Focused leader in medication-assisted treatment (MAT) for addiction Our Vision No. 1 position in largest MAT market (U.S.) For all patients around the world to have Double-digit market growth in U.S. access to evidence- based treatment fo
Slide 5: Our aspiration remains leveraging approved depot technologies to expand our platform
Our aspiration remains leveraging approved depot technologies to expand our platform globally and create greater value Short-to-medium Longer term Expected benefits term focus aspiration Renewed profitable Depot technologies Other substance use growth disorders U.S. core market Balanced mix Early st
Slide 6: SUBLOCADE
SUBLOCADE™ (buprenorphine extended-release) Injection
Slide 7: National drug overdose deaths involving any opioid: 1999-2017
National drug overdose deaths involving any opioid: 1999-2017 47,600 Understanding the epidemic 700,000 people have died from a drug overdose from 1999 to 2017(1) 130 Americans die every day from opioid 18,515 overdose (on average)(1) 8,048 68% of the more than 70,200 drug overdose deaths in 2017 in
Slide 8: Sustainable structure in place to help accelerate OUD patient treatment
Sustainable structure in place to help accelerate OUD patient treatment in the US with SUBLOCADE™ ▪ Waivered HCPs - 61,500 in FY18 and growing(1) ▪ Increased Federal government funding available - $11 bil. across 57 programs(2) ▪ High-quality payor access - 85%+ of patients with public or private in
Slide 9: SUBLOCADE product profile
SUBLOCADE™ product profile(1) The only once-monthly – SUBLOCADE™ is designed to deliver therapeutic levels of buprenorphine at a controlled rate over a one-month period Sustained plasma concentrations of buprenorphine ≥2 ng/mL for a month Blocks the rewarding effects of opioids (1) Please refer to f
Slide 10: Accelerating SUBLOCADE NR trajectory to $1 billion target
Accelerating SUBLOCADE™ NR trajectory to $1 billion target 1 Enhanced patient & HCP engagement 2 Channel development 3 Accelerate leadership in addiction treatment advocacy 10
Slide 11: Enhanced patient & HCP engagement – promotional levers are in place
1 Enhanced patient & HCP engagement – promotional levers are in place ▪ 6 Peer-reviewed $704.78 ▪ Translating science into ▪ Policy (Federal & State) publications patient benefits ▪ Direct-to-consumer (DTC) ▪ 13 Conference ▪ Includes request for ▪ Public relations presentations OPDP comments Recogni
Slide 12: Channel development on track – unlocking Organized Health Systems
Channel development on track – unlocking Organized Health 2 Systems (OHS) From: Single HCP & Clinics To: Organized Health Systems + Core Integrated Delivery Networks Federal Health Systems Organized Customers (Consolidated hospital groups) (VA, DOD, Justice System) (Multi-site and multi-state clinic
Slide 13: Accelerate leadership in addiction treatment advocacy
3 Accelerate leadership in addiction treatment advocacy – vocal support for bipartisan action combating the opioid epidemic Bipartisan support for help(1) Increasingly being felt on the front lines $11 bil. across 57 federal programs Record growth in waivered MDs in so far in FY2019(2) (~9,000) $2.1
Slide 14: New national DTC campaign – Keep Moving Towards Recovery
New national DTC campaign – Keep Moving Towards Recovery https://www.sublocade.com/tv-ad 14
Slide 15: PERSERIS
PERSERIS™ (risperidone) for extended-release injectable suspension
Slide 16: PERSERIS is delivering against launch plan
PERSERIS™ is delivering against launch plan ▪ Managed Care Access - 93% overall; 80% at parity ▪ Channel/Distribution - Open network; contract secured with Genoa (largest SP for LAIs) ▪ New HCPs - Ahead of analogue; proof that concept attractive ▪ Traditional Sample Program - Working seamlessly and
Slide 17: YTD 2019 Progress
YTD 2019 PROGRESS
Slide 18: DOJ matter
DOJ matter On April 9, 2019, a federal grand jury in the Western District of Virginia indicted the Company on charges of health care fraud, wire fraud, mail fraud, and conspiracy, in connection with the Company’s marketing and promotion practices, pediatric safety claims, and overprescribing of SUBO
Slide 19: YTD 2019 snapshot
YTD 2019 snapshot YTD Financial Performance YTD 19 Operating Discussion (adjusted basis(1)) 2019 vs. 2018 (adjusted basis(1)) • BMAT market: Continued double-digit growth in U.S. mainly driven by government channels Net Rev. $652m -15% • Net Revenue: U.S. NR decline (-16%) reflected SUBOXONE® (bupre
Slide 20: Why Indivior?
Why Indivior? Most experienced and recognized leader in BMAT for opioid use disorder (OUD) Diversifying into co-occurrences of OUD via Behavioral Health (schizophrenia) Proven innovator of differentiated depot technologies that address treatment gaps Singular focus is growing SUBLOCADE™ patient requ
Slide 21: SUBOXONE Sublingual Film indication and highlighted safety information
SUBOXONE (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM (CIII) INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBOXONE Film is indicated for the treatment of opioid dependence. SUBOXONE Film should be used as part of a complete treatment plan that includes counseling and psychosocial support
Slide 22: SUBLOCADE indication and highlighted safety information
SUBLOCADE (BUPRENORPHINE EXTENDED-RELEASE) INJECTION FOR SUBCUTANEOUS USE (CIII) INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-cont
Slide 23: About PERSERIS
ABOUT PERSERIS™ (risperidone) for extended-release injectable suspension INDICATION PERSERISTM (risperidone) is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed
Slide 24: Appendix
Appendix So INDIVIOR
Slide 25: Q3 Profit & Loss Account Reconciliation
Q3 Profit & Loss Account Reconciliation (1) Q3 2019 Q3 2018 2019 2019 2018 2018 Adjustments Adjustments Actual Adjusted Actual Adjusted ($ in mil.) Net Revenues 199 199 245 245 Cost of Sales (34) (34) (35) (35) Gross Profit 165 165 210 210 Selling, General and Administration Expenses (97) (97) (123)
Slide 26: YTD Profit & Loss Account Reconciliation
YTD Profit & Loss Account Reconciliation YTD 2019 YTD 2018 2019 2019 2018 2018 Adjustments Adjustments Actual Adjusted Actual Adjusted ($ in mil.) Net Revenues 652 652 768 768 Cost of Sales (97) (97) (93) (93) Gross Profit 555 555 675 675 Selling, General and Administration Expenses (299) (28) 1 (27
Slide 27: FY 2019 guidance (revised October 15th)
FY 2019 guidance (revised October 15th) ($ in mil.) Revised Guidance Previous Guidance Net revenue $750m — $790m $670m — $720m Net income (adj.) $160m — $190m $80m — $130m Top-line: Expenses: • U.S. buprenorphine/ naloxone film market conditions • OPEX of $440m to $460m, including current Litigation
Indivior — Fall 2019 Healthcare Conferences (Stifel NYC, Jefferies London) on 6ix